Completed PHASE4 INTERVENTIONAL 3-arm NCT00309465

Perioperative Insulin Glargine Dosing Study

A Study of the Relationship Between the Proportional Insulin Glargine Evening Dose and the Perioperative Serum Glucose Values in Patients With Diabetes Undergoing Surgery

Sponsor: Sanofi

Conditions Diabetes Surgery

Interventions Insulin Lantus

Updated 9 times since 2017 Last updated: Nov 1, 2012 Started: Oct 31, 2005 Primary completion: Oct 31, 2008 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes and Surgery and is currently completed. Sanofi leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Jan 2026 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi
Tamra Dukatz

Data source: Corewell Health East

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Royal Oak, United States
• Troy, United States